Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. May 7, 2016; 22(17): 4275-4286
Published online May 7, 2016. doi: 10.3748/wjg.v22.i17.4275
Table 2 Clinical trials of immune checkpoint therapy in patients with colorectal cancer
TargetImmunotherapyPhasePatientsResultsRefYear
PD-1Pembrolizumab, anti-PD-1 immune checkpoint inhibitorII11 MMR-deficient CRC, 21 MMR-proficient CRC, and 9 MMR-deficient non-CRCThe immune-related objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patients) and 78% (7 of 9 patients), respectively, for MMR-deficient CRC and 0% (0 of 18 patients) and 11% (2 of 18 patients) for MMR-proficient CRCLe et al[89]2015